title: Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery.
abstract: Various approaches are currently proposed to successfully develop therapies for the prevention and treatment of infectious diseases and cancer. One of the most promising approaches is the development of vaccines that elicit cytotoxic T lymphocyte (CTL) responses. Consequently, identification and exact definition of molecular parameters involved in peptide-MHC class-I interactions of putative CTL epitopes are of prime importance for the development of immunomodulating compounds. To better facilitate epitope discovery, we developed and validated a novel state-of-the-art biochemical HLA-A0201 assay, which is comprised of technologically advanced cutting edge reagents. The technique is based on competition and uses a FITC-labeled reference peptide and highly purified soluble HLA-A0201 molecules to quantitatively measure the binding capacity of nonlabeled peptide candidates. Detection by fluorescence polarization allows real-time measurement of binding ratios without separation steps. During standardization, the problem of assay parameter variation is discussed, showing the dramatic influence of HLA and reference peptide concentrations as well as the choice of the reference peptide itself on IC(50) determinations. For validation, a panel of 15 well-defined HLA-A0201 ligands from various sources covering a broad range of binding affinities was tested. Binding data were used to compare against pre-existing quantitative assay systems. The results obtained demonstrated significant correlation among assay procedures, suggesting that the application of fluorescence polarization in combination with recombinant sHLA molecules is highly advantageous for the accurate assessment of peptide binding. Furthermore, the assay also features high-throughput screening capacity, providing uniquely efficient means of identifying and evaluating immune target molecules.
authors.affiliation: Pure Protein L.L.C., Oklahoma City, Oklahoma 73104-3698, USA. rico-buchli@ouhsc.edu
authors.forename: Rico
authors.initials: R
authors.lastname: Buchli
authors.forename: Rodney S
authors.initials: RS
authors.lastname: VanGundy
authors.forename: Heather D
authors.initials: HD
authors.lastname: Hickman-Miller
authors.forename: Christopher F
authors.initials: CF
authors.lastname: Giberson
authors.forename: Wilfried
authors.initials: W
authors.lastname: Bardet
authors.forename: William H
authors.initials: WH
authors.lastname: Hildebrand
mesh_terms: D001665:Binding Sites; D000939:Epitopes / Q000032:analysis; D016650:Fluorescein-5-isothiocyanate; D015497:HIV-1 / Q000276:immunology; D015234:HLA-A Antigens / Q000737:chemistry* / Q000378:metabolism; D015789:HLA-A2 Antigen; D006515:Hepatitis B virus / Q000276:immunology; D006801:Humans; D010455:Peptides / Q000737:chemistry / Q000378:metabolism; D011994:Recombinant Proteins / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism; D013050:Spectrometry, Fluorescence
chemical_list: D000939:Epitopes; D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; D015789:HLA-A2 Antigen; D010455:Peptides; D011994:Recombinant Proteins; D016650:Fluorescein-5-isothiocyanate